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METHODOLOGY Open Access
Pre-referral rectal artesunate in severe malaria:
flawed trial
Karim F Hirji1* and Zulfiqarali G Premji2
Abstract
Background: Immediate injectable treatment is essential for severe malaria. Otherwise, the afflicted risk lifelong
impairment or death. In rural areas of Africa and Asia, appropriate care is often miles away. In 2009, Melba Gomes
and her colleagues published the findings of a randomized, placebo-controlled trial of rectal artesunate for
suspected severe malaria in such remote areas. Enrolling nearly 18,000 cases, the aim was to evaluate whether, as
patients were in transit to a health facility, a pre-referral artesunate suppository blocked disease progression
sufficiently to reduce these risks. The affirmative findings of this, the only trial on the issue thus far, have led the
WHO to endorse rectal artesunate as a pre-referral treatment for severe malaria. In the light of its public health
importance and because its scientific quality has not been assessed for a systematic review, our paper provides a
detailed evaluation of the design, conduct, analysis, reporting, and practical features of this trial.
Results: We performed a checklist-based and an in-depth evaluation of the trial. The evaluation criteria were based
on the CONSORT statement for reporting clinical trials, the clinical trial methodology literature, and practice in
malaria research. Our main findings are: The inclusion and exclusion criteria and the sample size justification are
not stated. Many clearly ineligible subjects were enrolled. The training of the recruiters does not appear to have
been satisfactory. There was excessive between center heterogeneity in design and conduct. Outcome evaluation
schedule was not defined, and in practice, became too wide. Large gaps in the collection of key data were
evident. Primary endpoints were inconsistently utilized and reported; an overall analysis of the outcomes was not
done; analyses of time to event data had major flaws; the stated intent-to-treat analysis excluded a third of the
randomized subjects; the design-indicated stratified or multi-variate analysis was not done; many improper
subgroups were analyzed in a post-hoc fashion; the analysis and reporting metric was deficient. There are concerns
relating to patient welfare at some centers. Exclusion of many cases from data analysis compromised external
validity. A bias-controlled reanalysis of available data does not lend support to the conclusions drawn by the
authors.
Conclusions: This trial has numerous serious deficiencies in design, implementation, and methods of data analysis.
Interpretation and manner of reporting are wanting, and the applicability of the findings is unclear. The trial
conduct could have been improved to better protect patient welfare. The totality of these problems make it a
flawed study whose conclusions remain subject to appreciable doubt.
Background
While severe malaria requires urgent attention, patients
with the disease often reside far away from health facil-
ities equipped to perform accurate diagnosis and admin-
ister suitable parenteral treatment. They may not be
able to take oral medication, and face a high risk of
permanent disability or death. Can that risk be reduced
by an artesunate suppository placed as the patient
embarks on the possibly long journey to a clinic? By
rapidly lowering parasitemia, rectal artesunate may
impede progression of the disease sufficiently to
decrease the chance of a grave adverse outcome occa-
sioned by the delay in securing appropriate treatment.
Gomes et al. [1] (hereafter referred to without the cita-
tion number) report a clinical trial undertaken to test
this hypothesis.
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Done under the auspices of the WHO and funded by
major multilateral agencies, it took place at four centers
(one in Bangladesh, one in Ghana, and two in Tanza-
nia). Involving a sizeable team of experts, its design,
conduct and analysis were overseen by a renowned clin-
ical trial center. Almost 18,000 people with suspected
severe malaria not able to take medication by mouth
received an artesunate or a placebo suppository. The
outcome was assessed in terms of death by 7 to 30 days
(D), or permanent disability (PD).
The main finding was that among the cases who took
more than 6 hours to reach a health clinic, “pre-referral
rectal artesunate significantly reduced death or perma-
nent disability (29/1566 [1.9%] vs 57/1519 [3.8%], risk
ratio 0.49 [95% CI 0.32-0.72], p = 0.0013).” The authors
unequivocally conclude: “If patients with severe malaria
cannot be treated orally and access to injections will
take several hours, a single inexpensive artesunate sup-
pository at the time of referral substantially reduces the
risk of death or severe disability.”
This trial is the largest trial ever done for severe
malaria, and the only reported trial of this intervention
for the noted circumstances. A comment in the same
journal lauds it for providing “clear answers to several
questions ...” [2] Two postings on the WHO website
give additional information and explanations about the
trial [3,4]. Gomes et al. went on to win the prestigious
BMJ Group Award for the Research Paper of the Year
for 2010 [5]. The accompanying editorial in the BMJ
described it as a “remarkable study“ that signified “an
outstanding logistical feat.” [6]
This high profile trial has already had an impact on
the global malaria policy. Earlier, supportive data from
smaller hospital-based studies had led the World
Malaria Report 2008 to recommend rectal artesunate as
a pre-referral treatment for severe malaria in children
under five [7](page 4). The publication of this trial put
that recommendation on a firmer footing, and now it
has been broadened to all cases with severe malaria [8]
(page 3). The principal findings of this trial have been
incorporated into other international guidelines for the
treatment of malaria, and used to justify pre-referral rec-
tal artesunate as a cost-effective intervention [9,10].
Only one letter to the editor questioning the use of a
placebo in the trial broke this mould [11]. For a single
trial to have such a recognition and impact, and within
such a short time, is a rare event in the modern era.
For trials that address major health issues, it is neces-
sary to check that they were designed and conducted
according to required high standards, and their conclu-
sions emanate from a sound interpretation of the find-
ings. The paper by Gomes et al. has not undergone an
independent quality review in the context of a systema-
tic review. We thereby undertook to perform an in-
depth evaluation of the scientific validity of the trial,
and the reliability of its conclusions, and to gauge the
contextual ramifications of its design and implementa-
tion, including their impact on patient welfare.
Results and Discussion
We began with an assessment of the quality of Gomes
et al. by using an extended version of the Jadad scale
[12]. The items in this scale are often employed to
assess trial quality in systematic reviews. The seven
quality assessment items we used are shown in Table 1.
Our subsequent detailed assessment was performed
along five principal lines: (i) trial design; (ii) trial con-
duct; (iii) data analysis; (iv) interpretation; and (v) con-
textual issues including patient welfare. In this task, we
used generally accepted quality criteria for the internal
validity of clinical trials in the literature and as reflected
in the CONSORT Statement [13,14]. Trial features that
pertain to external validity were also examined [15-17].
Where possible, reporting quality was separated from
substantive quality. Other than this, we did not have a
formal evaluation scheme. We present our findings as a
narrative-based review in which we lay out the evidence
and line of reasoning we employed to reach our
conclusions.
Where needed and if feasible, we reanalyzed the trial
data using either the methods used by the authors, or
different methods, as implemented in the package WIN-
PEPI [18]. The specific methods are noted in the rele-
vant sections. All unsourced quotes in this paper are
from Gomes et al. In addition to the WHO website
postings noted above, two papers that either draw upon
the original trial data, or concurrently interviewed a sub-
set of trial participants, provided additional relevant
information. The first paper, Kitua et al. [19], examines
the ethics of using a placebo in this trial, and the sec-
ond, Gomes et al. [20], reports a parallel investigation
done at one trial center. The principal author and sev-
eral co-authors of each paper participated in the trial.
Table 1 Checklist assessment of Gomes et al.
Trial Feature Yes/No
1. Randomization methods described? Yes
2. Randomization concealment adequate? Yes
3. Blinding level appropriate and adequate? Yes
4. Patient flow chart given? Yes
5. Attrition bias low or not present?* Yes
6. Intent-to-treat analysis used?* Yes
7. Overall drop out level ≤ 10%?* Yes
Total Score (Yes = 1, No = 0; Maximum = 7) 7
Note: Items in the checklist based on Jadad and Enkin [12] and the CONSORT
statement [13]; *As stated by the authors.
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Synopsis
This trial was double blind with a treatment allocation
scheme that was random and adequately concealed.
Only eight cases were said to be completely lost to fol-
low-up. The data analysis is stated to have followed the
intent-to-treat principle. According to the items in
Table 1 and taking the descriptions given by the authors
at face value, this trial secures a perfect score, implying
that it is of high quality. On the other hand, our assess-
ments revealed that it had major flaws in all the five
main facets we looked at. We detail these findings
below.
Trial Design
A child in a remote village has high fever, and may be
vomiting, convulsing, or comatose. The signs indicate
severe malaria but that cannot be confirmed. A pill by
mouth is not feasible. Injectable drugs are unavailable.
Should an artesunate suppository be placed before the
child is sent to a health clinic where the required diag-
nostic tools and treatment are available? That is the
basic question Gomes et al. tackle.
Half of the randomized cases in this four-center study
were in Africa, and half in Bangladesh. All centers used
identical active and placebo treatments, and the rando-
mization scheme was stratified by center and blocked. A
core common design was developed, and was subse-
quently “adapted“ for each country.
Between center differences in terms of disease charac-
teristics and baseline risk are, to a degree, inevitable in a
multi-center trial. For example, the Bangladesh sites
were in low malaria transmission localities but at the
African sites, the levels of transmission were high. The
parasite subtype distributions in Bangladesh and Africa
differed. The hallmark of a multi-center trial, neverthe-
less, is commonality of basic design features across the
centers. When applied appropriately, this design can
provide better insight into the applicability of the find-
ings of the study.
In this trial, a number of features that should have
been similar across the centers were not. For example:
African centers enrolled children up to the age of
seventy-two months but in Bangladesh, older children
and adults were recruited as well. The cases in the latter
had free hospital and supportive care. In Africa nothing
like that was arranged. At the referral clinic in Bangla-
desh, intravenous quinine was given. In Africa, intra-
muscular injections were given. There were about two
recruiters per village, on average, in Africa; in Bangla-
desh, there was exactly one recruiter per village. The
calibre of the recruiters, and the training schemes per-
haps differed. One blood slide per case was taken in
Africa but two were taken in Bangladesh. The types of
data collected varied somewhat. The African centers
themselves had differences in design. We give more
details later. These differences put this trial in the grey-
zone between a well designed multi-center trial, and a
collection of two, three or four distinct trials with their
own protocols. This fact has profound implications for
data analysis, interpretation of the findings, and future
meta-analysis. We elaborate on these points later.
The tested treatments, randomization scheme, and
settings are adequately described in the paper, as
required by the CONSORT statement [13]. Two out-
comes, death and PD, are declared as the primary end-
points (main outcomes). A number of key items,
however, are partly specified or missing. The omissions
cast a shadow on what actually happened. These items
are (i) sample size computation; (ii) eligibility criteria;
(iii) nature of training for trial recruiters; (iv) the time
plan for follow-up of the subjects; and (v) quality assur-
ance for blood slide readings.
The absence of sample size computation information
in a trial guided by a prominent clinical trial center may
be a reporting oversight. We also do not know the basis
on which the total size was apportioned across the cen-
ters. Such information not only tells us if the trial had
high power to detect realistic differences but also assists
us, in the absence of protocol deviations, to judge the
assumptions made, identify primary outcome(s), effect
measure, relevant data analysis method, and the levels of
loss to follow-up and missing data [21].
As the analysis employed three main outcome vari-
ables (D, PD, and D or PD), we used a Bonferroni
adjusted a = 005/3 = 0.0167 to compute the sample
size needed in a two group design to detect a differ-
ence in an outcome of 1.0% and 2.0% with 90% power.
This turned out to be n = 8000. The trial size thus suf-
ficed to detect such a difference. But, our computation
assumed negligible between center heterogeneity,
which was not the case. Extensive post-hoc subsidiary
analyses, with some being accorded primary impor-
tance, were also done. That increases the a-error mak-
ing the statistical significance of any comparison
difficult to judge.
A clear declaration of the inclusion and exclusion cri-
teria is an essential feature of trial reports [13,14].
Gomes et al. state in several places (but in not quite
consistent ways) that they recruited cases with symp-
toms of severe malaria who could not take oral drugs
and the methods section mentions recruitment of
“patients meeting eligibility criteria.” But the signs and
symptoms the recruiters were trained to identify and
use for inclusion and exclusion are nowhere explicitly
noted, and center or country-wise differences in these
criteria are not mentioned. That the age ranges for the
three countries were not the same indicates that each
had its own criteria. Also, the list of inclusion but not
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the exclusion criteria at one Tanzania center for this
trial appear in another paper published a year later [20].
Trials in rural settings may not have the elaborate
eligibility criteria of hospital-based trials. Yet, they do
need some criteria, however rudimentary. And, even
these need to be stated clearly and unambiguously.
The study population is not described consistently.
The Methods part in the Summary says that “patients
with suspected severe malaria ....” were recruited, but
the Interpretation part gives recommendations for
“patients with severe malaria ...“ Another paper derived
from this trial states that the “study population com-
prised patients with suspected severe malaria ....” but
then reports data analysis for only those with confirmed
malaria [19].
The type of recruiters deployed and their training is a
critical and related issue. Rural trials often employ com-
munity health workers, nursing assistants, medical assis-
tants, local midwives, medicine sellers or even
traditional healers in that role. These village health
workers (VHW) undergo further training on diagnosis,
enrollment decisions, drawing blood samples, adminis-
tering treatment, maintaining basic records and per-
forming other tasks. For example, in a trial of intra-
rectal quinine alkaloids for severe malaria, Thera et al.
[22] involved employees at rural health facilities who
underwent additional training, the aims and content of
which are clearly stated. In a study of home manage-
ment of malaria, Ajayi et al., [23] used community medi-
cine dispensers and field supervisors. All attended
workshops to learn specifically noted techniques and
matters. The former also underwent a refresher course
one month after initial training.
The key point is to use people already immersed in
the provision of health care at some level, and give
them suitable training, the nature and duration of which
are well described either in the report, or in a referenced
document. An example of the latter is WHO [24]. The
more serious the disease, the higher are the standards
for trainees and training that need to be adopted.
Gomes et al. does not compare well with the above
noted trials in this regard. They used 417 “resident vil-
lage recruiters,” most of whom had “little previous medi-
cal knowledge and no research experience,” who then
“underwent one to three weeks of training.” [1,3] The
kind of training given is not described in the paper nor
the website material. It is not clear why some were
trained for a week and others for three weeks, and
whether the calibre of the trainee recruiters and the
training protocol varied by center or not. The recruiters
are stated to have been supervised every few days by a
team of 74 field supervisors named at the end of the
paper. But their qualifications, and the additional train-
ing they received, if any, are not described [1,3].
The WHO website material is inconsistent with the
paper. The website describes the recruiters slightly dif-
ferently as persons with “little or no previous medical
knowledge ..“ and are inaccurately referred to as “village
health workers.” [3] A related paper calls them “semi-
trained village health worker[s]“ in one place and “com-
munity health worker[s]“ in another, but does not spell
out what the terms mean [20]. Kitua et al. [19] says that
in this trial “community-based recruiters were trained to
identify patients (with clinically suspected malaria, who
could not take oral medication) early in the evolution of
the disease, to randomise them to a single dose rectal
artesunate or identical placebo, and immediately refer
each patient to medical facility ...“ But, the nature and
duration of the training, or whether the recruiters were
trained to draw blood, make blood slides, note date of
birth and sex, and accurately fill out the entry form and
referral slip are not mentioned.
The information about training and trainees in this
trial is scanty, not always consistent, and scattered in
several papers and sources. It requires a resourceful
reader to unearth them. The phrase “community” or
“village health worker” has an official definition that var-
ies in different national contexts [25]. Lack of clear ter-
minology on such matters impedes appropriate
interpretation and practical translation of research
findings.
Another design-related concern is the time window
for initial follow up. Most severe malaria studies assess
short term or in-hospital mortality (see Table one in
Maitland [26]). Akech et al., [27] however, followed up
severe malaria cases after discharge. Of the 241 patients
enrolled, 213 were discharged alive. By tracking them
through an established demographic surveillance pro-
gram, 196 were confirmed alive in the 21 to 35 day per-
iod after discharge. The short term (in-hospital)
mortality here was 11.2% and cumulative medium term
(up to 35 days) mortality was 18.3%. The cohort study
of Phiri et al. [28] also indicates continued higher post-
discharge risk of death among severe malaria cases.
The first follow-up window in Gomes et al. trial is sta-
ted as 7 to 30 days after entry. The first follow-up “took
place, on average, at day 14.” Even while it refers to
curves that look like survival curves (Figure two of
Gomes et al.), it is unclear if this is a median or mean
value. No other details like median follow-up time by
treatment arm or center are provided. In any case, it
implies that some patients were possibly first followed
up on day 8, some on day 29, etc. Those followed up
early were assessed for short term mortality, while those
followed up towards the end of the period, for cumula-
tive medium term mortality. This obscures clinical inter-
pretation of the results as apples are mixed with
oranges. Also we do not know whether the follow-up
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window was set by design, or if it was a post hoc reflec-
tion of what occurred in practice. The wide follow-up
window also compromised the data analytic strategy
used (see below).
Quality control for blood slides is not mentioned.
Confirmatory diagnosis is essential in severe malaria.
Blood slides results need quality control [29,30]. During
the parasite sequestration stage, moreover, peripheral
parasite density in severe malaria can be low or even
negative.
For each issue noted above, the extent of between
center variation bears on the interpretation of the
results. Yet, hardly any relevant details are given.
The example of Yeboah-Antwi et al. [31] is useful to
obtain a comparative perspective. This paper reports a
trial of community management of fever in rural Zam-
bia. With a cluster randomized design and sample size
of 3125 children, the aim was to see if VHWs could be
trained to distinguish between and treat uncomplicated
malaria and non-severe pneumonia effectively.
In Table 2, we compare the adequacy of reporting of
design features for this trial with that of Gomes et al.
Unlike the latter, the Zambia trial report gives sufficient
details on sample size calculations, eligibility criteria,
and prespecified primary and secondary outcomes. The
background of the VHWs, and the methods, content,
type and duration of training given to them, and the
skills assessment and supervision done are described in
depth. The planned follow-up window is precisely sta-
ted. The trial protocol and training manuals are posted
on the journal website as supplementary files [31].
While this report stands at the high end of the good
reporting scale, and most rural trial reports would fall
somewhere in between, our impression is that Gomes et
al. would fall below the half-way level on that scale.
Implementation
An apparently positive feature of the trial was that only
eight out of the nearly 18,000 subjects were completely
lost to follow-up. We say apparently because first, the
follow-up schedules set in the trial protocols are not
known, and second, what under one way of analyzing
the data looks as a high loss to follow-up level can,
under another way of analyzing them, become a low
loss to follow-up level. This point is elaborated in the
next section.
There were two other major implementation-related
shortcomings, namely, (i) recruitment of clearly ineligi-
ble subjects, and (ii) failure to collect key data for a
large number of subjects.
According to Figure one of the paper, the randomized
children fell into three subgroups (i) cases negative for
malaria (n = 4648), (ii) cases already treated by injection
for severe malaria (n = 1110), and (iii) subsequently con-
firmed malaria cases possibly needing injectable treat-
ment (n = 12068).
The randomization (enrollment) form for the trial
recorded whether the subject had had an immediate
prior injection for malaria or not. Cases in subgroup (ii),
6% of the total, were thus identifiable but clearly ineligi-
ble for this trial. Why did the recruiters randomize such
cases? Did this anomaly occur only at some centers?
What does it say about the training process? The
authors implicitly, after the fact, and without a clear
explanation, acknowledge the ineligibility of such sub-
jects by excluding them from all data analysis.
The number of cases in subgroup (i), almost 25% of
the total, is a related issue. Some possibly were false
negatives as peripheral parasite density in severe malaria
is negative in the sequestration phase. But presumably
most had pneumonia, meningitis or another infection.
Properly trained VHWs can differentiate between
malaria and pneumonia, and reduce child mortality
from these conditions [31,32]. A rapid diagnostic test
for malaria, which a VHW can be trained to use effi-
ciently, assists in this task [31,33]. Cheaper brands of
such tests were becoming available at the time this trial
began. At the community level, misdiagnoses of malaria
and severe malaria are inevitable. The point is to
Table 2 Adequacy of the reporting of trial design
features
Feature Reported and adequately described?
Gomes et al.
[1]
Yeboah-Antwi et al.
[31]
Protocol Publicly Available No Yes
Study Question Yes Yes
Study Population Inconsistent Yes
Basic Study Design Yes Yes
Treatment and Control Yes Yes
Inclusion Criteria Vague Yes
Exclusion Criteria No Yes
Primary Outcome(s) Unclear Yes
Secondary Outcomes Unclear Yes
Randomization Scheme Yes Yes
Blinding Level Yes Yes
Evaluation Schedule No Yes
Sample Size Computation No Yes
Statistical Methods Partial Yes
Background of Recruiters Vague Yes
Type and Duration of
Training
Vague Yes
Training Manual No Yes
Skills Assessment No Yes
Trained Data Collectors No Yes
Supervision Yes Yes
Informed Consent Yes Yes
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minimize erroneous diagnoses with adequately trained
VHWs, and perhaps a rapid diagnostic test. The training
done by Yeboah-Antwi et al. [31] is exemplary towards
achieving such a goal.
Now consider the issue of missing data, starting with
age. Table one of the Gomes et al., which reports base-
line comparisons, shows the age distributions by treat-
ment group in an incomplete way. Only subjects older
than 6 years for Bangladesh are fully compared. The
legend of the table refers to “apparent age,” and in the
text, there is reference to “assessed age.” (paragraph 1,
Results section). These terms are never defined, and we
are not told who did that assessment, and how it was
done. Another concern is that the “overall mean age”
for children in the artesunate group is given but is not
given for those in the placebo group, and the age distri-
butions by treatment group for children are not given.
Also, while the centers in Tanzania recruited children
with “assessed age“ between 6 to 60 months, the Ghana
center recruited children with “assessed age“ from 6 to
72 months. Why the difference? The bottom line is that
baseline comparison for a basic item like age is not fully
and clearly reported. Perhaps that was due to extensive
missing data on age. It seems that the problem was
more serious in the African centers.
Next, we note that at Handeni, a Tanzanian center,
“blood slides were not collected routinely during most of
the trial.” (Legend to Table one of Gomes et al.) In all,
about 17% of the cases included in the analysis from
Africa had no blood slide. For Bangladesh, this stood at
less than 1%. How was it determined if a case with no
slide actually had malaria? How were such cases
included in the analysis? No clear answers to these criti-
cal questions are provided.
This problem is related to the earlier observation that
cases in Bangladesh had two slides taken at enrollment
while those in Africa had only one. At all sites, one slide
was retained with the enrollment form for collection by
trial personnel. The extra slide in Bangladesh was taken
by the patient, together with the referral slip, to the
referral health facility, and used, perhaps with an addi-
tional newly made slide, for diagnosis. In Africa, a pre-
referral slide was not available at the health facility [20].
Since rectal artesunate rapidly lowers the peripheral
blood parasite count, the sole reliance on the slide taken
at health facility raised the chance of a false negative in
the artesunate arm compared to the placebo in Africa.
Therefore, an African case with severe malaria in the
artesunate arm had a higher chance of delayed treat-
ment for severe malaria, thus affecting outcome and the
internal validity of the trial.
Another item with many missing values is time to
reach the clinic. This is a critical data item for this
paper, in that apart from Table one and Figure one, all
the other tables and figures in the paper (Tables two,
three and four and Figures two, three and four) relate to
it. Most of the analyses in the Results section pertain to
it. And it is these analyses that generate the conclusion
that the real benefits of pre-referral rectal artesunate for
severe malaria become evident only when we account
for time to arrival at the referral clinic.
Yet, the Legend to Table three states that time to
clinic “was recorded routinely only in Kilosa and Nav-
rong.” That is, only two African sites, with fewer than
half of the eligible randomized subjects, regularly gath-
ered data for a variable which underpins the bulk of the
analysis done. To make up for this shortfall, the analysis
made a reasonable guess for the value of this variable
for a subject with a missing value. The authors assumed
that 95% of the cases reached the referral clinic within
six hours, and 50% of the cases at Handeni, the third
African site, were assumed to have reached the clinic
within this window.
The favorable arrangements under which most
patients were expected to, and promptly did, go to a
hospital in Bangladesh may explain why it was not in
the routine data collection plan. Thereby, usage of the
variable “time to clinic” in the analysis was a post-hoc
decision. The bulk of the analysis presented, and which
lead to the principal recommendations of the trial, is
thus seen not to derive from field data but from not
well justified imputations for a crucial data item for up
to 50% of all the subjects used in the analysis.
Even where it was recorded, we do not know who
recorded the time to clinic, and how precisely it was
defined. For example, in Kilosa, patients often first went
to a smaller health clinic they were referred to by the
recruiter and later landed in the main district hospital
where the required or further treatment was given.
Gomes et al. define it as “time to reach a facility at
which injections could be given“ while a related paper
with the same main author specifically deals with time
to reach the district hospital [20].
The recruitment of clearly ineligible subjects, the
missing slides, problems of data collection and the con-
cerns about the quality of some data items do not
reflect positively on the training and supervision at the
African (especially Tanzanian) sites, and the types of
recruiters they used.
Conflicting Descriptions
Gomes et al. [20] report a parallel study done at Kilosa,
a trial center in Tanzania, whose aim was to assess the
impact of the referral advice given to the trial partici-
pants. The authors interviewed the guardians or parents
of 936 children admitted at Kilosa district hospital dur-
ing the time the trial was underway. Of these children,
880 were enrolled in the trial and 156 were regular
admissions. Of interest is the following statement.
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“Patients were assessed for admission by the admitting
clinical officers who were unaware of whether patients
were included in the community-based study.” [20] The
community based study in question is the trial of
Gomes et al.
Kitua et al. [19] provide a detailed justification of the
ethics of using a placebo in the Gomes et al. trial. This
paper stresses that protecting the welfare of the patients
was a major consideration in the trial. Arrangements
were made to enhance adherence to referral advice, and
assure appropriate care once the patient arrived at a
health facility. We leave some aspects of this matter for
later discussion. Of interest for now is the following
statement. “In Tanzania, patients were provided with a
referral slip identifying them as a study child, their enti-
tlement to free hospital care was reinforced.” [19]
If specific steps were indeed taken to identify the trial
participants so as to assure them free quality care, it is
difficult to see how the blinding in terms of trial partici-
pation that Gomes et al. [20] note could have been
enforced. Hence the situation in this regard is unknown
What Kitua et al. [19] say is in line with the main
report, and casts a negative light on the validity of the
parallel study of Gomes et al. [20]. We note that the
main author of each of these papers is a co-author on
the other paper, and both are co-authors of the main
trial paper.
These conflicting statements about an important fea-
ture of the trial from the trial investigators together
with the other incomplete, vague or inconsistent
descriptions noted elsewhere reinforce the impression
that the reportage in Gomes et al. is substantially defi-
cient. An independent audit of trial records may be
needed to clearly establish what transpired during the
course of the trial.
Analysis and Interpretation
The data analyses presented in Gomes et al. are ser-
iously deficient in eight ways. These are: (i) ambiguous
primary end points; (ii) incorrect analyses of time to
event data; (iii) flawed intent-to-treat analysis; (iv)
absence of an overall analysis; (v) absence of design indi-
cated stratified or multi-variate analysis; (vi) analysis of
improper subgroups; (vii) excessive post-hoc analyses;
and (viii) the use of a less than desirable analysis and
reporting metric.
Before we elaborate, we reiterate an observation made
earlier, that the extent of center-specific variability
places this study somewhere between a bona-fide multi-
center trial, and two or three or four separate trials. The
authors faced three basic options for the main analysis
of the data. One, analyze and report as separate trials.
Two, analyze as for a multi-center trial employing meth-
ods for stratified data. And three, just add the numbers
from all centers, and analyze as for a single trial with a
uniform protocol. The extent of design-based heteroge-
neity, and the paradoxes associated with it, make the
last option the least advisable [34]. But it was the option
selected by Gomes et al. This affects both the interpreta-
tion of the findings, and the conduct of future systema-
tic reviews. We elaborate on this when we discuss the
issue of stratified analysis below.
Ambiguous Primary End Points
The primary endpoint in a clinical trial is specified in
the trial protocol, used in sample size computation at
the planning stage, and, once the trial is over, is used in
the main data analysis and for reporting the results in
the abstract. It should be clearly identified as such in
the methods section of the report. There may be more
than one primary end point, but trials with more than
three primary endpoints are rare. The terms primary
outcome and main outcome are synonyms. One primary
end point then corresponds to one outcome variable in
the analysis.
Gomes et al. clearly state, with different wordings, in
three places (Summary-Methods; Methods-Outcomes;
Methods-Statistical Methods) that the study had two
primary endpoints, namely 7-30 day mortality and per-
manent disability. However, in the Results section, we
read that “... the main analyses are of death or perma-
nent disability for 12068 patients with malaria ....” The
two primary endpoints thereby produce a third compo-
site endpoint that goes on to supersede them in impor-
tance. The bulk of the results presented in the Results
section of the Summary are in terms of this composite
outcome variable. And, by that point, the term mortality
has been reinterpreted as late mortality (death after six
hours).
Event or Time to Event?
The principal formal data analyses in Gomes et al. are in
terms of proportions. In a follow-up design, computing
a proportion assumes a fixed time window. Data analysis
for an uncomplicated malaria trial, for example, usually
evaluates a 14-day or 28-day treatment failure rate.
Minor variation in follow-up times, as in a window of
13-15 days for the 14-day rate, is inevitable and accepta-
ble. But if, as judged by the nature of the disease, times
to follow-up vary extensively, the appropriate course of
action is to analyze the data as time to event data.
Accordingly, Figure two of Gomes et al. shows the
cumulative death rate, and the cumulative D or PD rate
over time (by continent and treatment). The method
used for estimating the curves is not stated. Their first
portions (up to 7 days) treat the data appropriately as
time to event data. But in the second portions, the time
window is compressed, and simple proportions are
given. By presenting these as survival curves but not
exactly declaring them to be as such reduces clarity. A
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reader may take all the proportions as cumulative pro-
portions, and the last ones can be misinterpreted as the
30 day death (or D or PD) rates.
Take the outcome death. Three data items were avail-
able for each case: the day of the first follow-up visit,
the status of the patient on that day (dead or alive), and
if dead, the day of death. For those who died before day
7, either that fact became known at the time, or at a
subsequent follow-up visit. Since, except for the very
few cases with suspected PD, no further follow-up
occurred, the data are censored data that are usually
analyzed with survival data methods, or as person-day
data. Even if the main analyses were done in terms of
simple proportions, the authors could have shown the
appropriate cumulative proportions to day 30 in Figure
two with the Kaplan-Meier method. Appreciable varia-
tions in the follow-up times generally, by treatment arm
or by center can produce different results from different
methods of analysis.
Take a simple example: Suppose there were four cases
in each group, and the planned follow up was at 30 days
after entry. But, poor implementation caused it to be
done on an ad hoc basis. The respective days to death
data for the artesunate and placebo groups were: {8+, 9
+, 27, 28} and {8, 9, 27+, 28+}. Here, ‘+’ represents a
censored observation. Under the planned binary out-
come analysis of the 30 day survival rate, follow-up at
27 or 28 days may be deemed close enough and accep-
table. But the censored status of the first two cases in
the artesunate group is so far from the target day that
their final outcome would have to be regarded as
unknown, and their data treated as missing. To use
these early censored data, a survival analysis is needed.
Instead, Gomes et al. went ahead with the proportions-
based analysis but now under an expanded time window
of 7-30 days. This not only mixes up short term and
medium term mortality but also makes the loss to fol-
low-up rate appear lower than it really was. In this
example, the wide window makes the missing data rate
drop from 25% to 0%.
The wide window can also produce misleading results.
Under their analysis plan, the 7-30 day death rate is 50%
for both groups. Now suppose that the actual status of
the cases 30 days after entry was given by {24, 30+, 27,
28} and {8, 9, 30+, 30+}. The actual 30 day death rate
for artesunate is 75% and for placebo, it is 50%.
Note, if among those who did not experience an
event, a fixed minimum time of follow up was recorded,
it is legitimate to do both binary and survival types of
analysis. This was done, for example, for a community-
based diarrhea trial [35].
From a clinical perspective, the wide time window in
Gomes et al. is not useful or realistic. Together with the
binary analysis approach, it can mask the true rate of
missing data and yield conclusions that deviate from
underlying reality. Conceptually, continued medium
term risk of death makes a 7-30 day death rate for
severe malaria as valid as a 2-5 year death rate for a
cancer study.
Intent-to-Treat Analysis
Data analysis in a clinical trial should not be restricted
to the cases treated under ideal clinical conditions,
who behave as perfect cases and whose status is know
at all time points. Removing randomized cases from
analysis for violating such conditions not only affects
the applicability of the findings but also biases the esti-
mate of treatment effect [36]. To address these con-
cerns, an intent-to-treat (ITT) analysis (i) includes all
randomized subjects, and (ii) places each subject in the
group to which he or she was randomized [13,37,38].
This is done even if the case did not actually get the
allocated therapy, switched therapy, failed to take the
full dose, was misdiagnosed, should not have been in
the trial, was lost to follow-up, or underwent any other
experience. Subjects whose final outcomes are not
known are often assigned values that least favor the
adoption of the new treatment. The ITT approach
recognizes that treatment anomalies reflect real life,
protects the control of bias attained by randomization,
and reflects a precautionary approach towards using
the new intervention.
Gomes et al. included eight cases in whom the
inserted capsule was almost immediately expelled in the
analysis. Also, eight cases completely lost to follow-up
were included on the assumption that they all recovered.
Thus, they declare their analyses to be ITT analyses.
Yet, they excluded all the subjects in subgroups (i) and
(ii) from all analyses. They justify this act by stating that
the exclusion decision was taken prior to breaking the
blinding scheme. Nonetheless, removing a third of the
randomized cases from all the analyses is a major viola-
tion of the ITT principle. If a typical malaria trial has
about 500 subjects, the nearly 6000 randomized subjects
excluded from analysis is equivalent to dumping data
from 12 trials!
Excluding the cases with a prior injection from data
analysis represents, as noted, a modification for a design
or implementation-related flaw. Excluding patients with
negative slides, however, lacks a conceptual or practical
justification. The remote areas where the trial was con-
ducted and where its results would apply are areas
where confirmatory diagnosis of malaria or severe
malaria cannot be done. Whether in a trial or in prac-
tice, presumptive treatment prevails. Even with well
trained VHWs and a rapid diagnostic test, cases given a
suppository would later be found not to have malaria,
and some with malaria would be missed, especially if
they have a concurrent infection.
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We performed a true ITT analysis for this trial by
including all cases as randomized. The data for this
exercise were extracted from Figure one of the paper
(see Table 3). For the eight lost subjects, we posited
three scenarios. Scenario I assumed, as done by the
authors, that they were alive without PD. Scenario II
assumed they were dead, and scenario III assumed that
they were alive but with PD. The overall treatment
effect p-values for scenarios I, II and III are 0.18, 0.11,
and 0.027, respectively. The close follow-up for cases
with possible PD makes scenario III the least likely of
the three. And, even for scenario III, the p-values for
the individual outcomes are not significant at the 0.05
level when adjusted for multiplicity. An unbiased ITT
analysis with higher power thereby does not provide suf-
ficient evidence for a treatment-related difference for the
main outcomes. However, even these ITT analysis are
marred by the data quality and time window concerns
raised earlier.
We further discuss the authors’ justification for
excluding one third of the randomized subjects from the
data analysis when we address the practical concerns
related to this trial.
Overall Analysis
After excluding cases from subgroups (i) and (ii), the
authors are left with the following results: artesunate (D
= 154, PD = 2, Total = 6072), and placebo (D = 177, PD
= 12, Total = 5996). Even though they had two primary
endpoints (D and PD), they analyze these data in terms
of three binary outcome variables (D, PD, and D or PD)
and find that the p-value for D is not significant (0.1);
for PD, it is highly significant (0.002), and for D or PD,
it is at a borderline level of significance (0.048). The
observed difference in mortality is thus not statistically
significant when considered by itself but becomes barely
significant when it is combined with PD.
We avoid this quandary if we start with a combined
analysis of the outcomes and then, for separate outcome
comparisons, we adjust the p-values for multiplicity
[39]. This approach is consistent with a joint analysis of
the two original primary endpoints of the trial. It is the
approach we used in the ITT analyses above. For these
non-ITT data, using a three-valued outcome variable (D,
alive and PD, alive and no PD) gives a chi-square p-
value of 0.006, signaling the presence of an effect
beyond chance variation. Further, making separate com-
parisons under adjustments for multiplicity, we find that
only the difference in PD rates is significant.
The declaration of two primary end-points in the
Methods section indicates that the third composite out-
come variable (D or PD) was chosen post-hoc. Further,
no time factor is attached to the variable PD, making its
composition with D conceptually problematic. In the
Results section, primary and secondary outcome vari-
ables are not clearly distinguished. Also, note that even
the overall analysis we give is suspect because of the
wide window; because it is, like the authors’ analysis,
not an ITT analysis; and because it has not been done
in a stratified manner (see below).
Stratified Analysis
The randomization scheme and design-related heteroge-
neity between the centers call for a stratified form of
analysis. Figure two of Gomes et al., for instance, points
to a continent-wise heterogeneity of effect. Such an ana-
lysis would, to an extent, compensate for not publishing
as separate trials. Stratification allows us to adjust for
the differences in baseline risk and design factors into
the analysis. The main analyses done by the authors,
however, simply added the numbers from all the
centers.
Because center-specific data for subgroups (i) and (ii)
are not given, an ITT stratified analysis cannot be done.
In that case, using the same data as used by the authors
gives a comparative perspective. Table 4 has the data on
D or PD rates by treatment stratified by center. For
each center, the 95% CI for the risk difference (RD) for
D or PD includes the null value. We fitted a random
effects model [40] to estimate the overall RD. This
model allows for between strata heterogeneity by posit-
ing the stratum effect as a normally distributed random
variable with unknown but constant variance. The resul-
tant estimate of the RD was 0.006 with 95% CI
Table 3 ITT analyses under three scenarios
Status Scenario I Scenario II Scenario III
Artesunate Placebo Artesunate Placebo Artesunate Placebo
Dead* 258 288 258 296 258 288
Alive*& PD 15 22 15 22 15 30
Alive*& No PD 8681 8562 8681 8554 8681 8554
Total 8954 8872 8954 8872 8954 8872
p-value** 0.18 0.11 0.027
Note: These analyses include all the cases as randomized and use the data Figure one of Gomes et al. Scenario I assumes that the eight missing cases were alive
and without PD, scenario II assumes they were dead, and scenario III assumes they were alive but with PD; *Dead or Alive by day of 7-30 day follow up; **Chi-
square p-value.
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(-0.003,0.014). This result is not consistent with the
findings of the authors.
While the main analyses of Gomes et al. were not
stratified, some subsidiary analyses were. Thus, the pro-
portions who never reached the clinic among those who
survived more than 6 hours were analyzed, in a stratified
manner, by study center, and showed a marginal effect.
The reasons for doing a stratified analysis here but not
elsewhere are not given.
Reporting this study as a single trial without sufficient
strata level details bears on the conduct of a future sys-
tematic review. The level of heterogeneity may prompt
the reviewers to treat it as two, three or four separate
trials, as was done, for example, in a meta-analysis of
treatments for diarrhea [41]. But Gomes at al. does not
provide the basic data required for such a task. For
example, the numbers randomized to placebo and arte-
sunate are not given by continent or center.
Data Dredging and Subgroup Analysis
Analyzing data restricted to a subgroup of the study
subjects is called subgroup analysis. The medical litera-
ture abounds with warnings about the pitfalls of such
analyses [42-51]. Subgroup analyses are frequently over-
done, done post-hoc, and performed inappropriately,
and as such, raise the chances of producing flawed, false
positive conclusions.
The primary analyses of Gomes et al., which exclude a
third of the randomized cases, are, to begin with, sub-
group analyses. The greater portion of the additional
analyses further divides this subgroup into smaller sub-
subgroups. The division used most often separates those
who died within six hours and those who did not. Most
analyses exclude the former, as is evident from Tables
two, three and four, Figures three, four and five of
Gomes et al., and the amount of text devoted to these
tables and figures. The latter subsubgroup is decom-
posed into smaller and smaller entities (by region, time
to reach the clinic, age, comatose or not, etc.) for treat-
ment-wise comparison. For example, the treatment-wise
comparison of resolution of CNS damage giving p =
0.0037 employed only 44 of the 17,826 randomized
cases. As data-driven analyses are often reported selec-
tively, it is safe to say that the total number of such
analyses the authors did probably exceed those reported
in the paper.
None of the multitude of p-values is adjusted for mul-
tiplicity, and are difficult to interpret [52,53]. The
authors state (in the Discussion) that the “main finding
[of the paper] is based only on 3000 of the 18000
patients originally recruited ..“ Most of the results in the
Summary also derive from analyses of subgroups con-
structed within other subgroups.
Was subgroup analysis of any form pre-planned? The
authors say that “the cutoff of 6 h in our analyses was
not prespecified ...“ The bulk of the analyses uses this
cutoff. Since the data on time to reach the clinic were
not routinely collected at all centers, it is unlikely that
time to clinic-based analysis of any form was pre-speci-
fied. Unlike some other analytic decisions, we are not
told whether the use of the 6 hour cutoff was decided
prior to breaking the blinding code or not. It is not as
well explained why a 6 hour, rather than, say, a 12 hour
cutoff, was selected.
A serious concern is that most of the subgroup ana-
lyses in the paper are in fact the most proscribed
forms of subgroup analyses. To grasp this point, note
that subgroups are of two types: those defined by base-
line features, and those defined by an event or feature
that is manifested after randomization. Analysis of the
former is acceptable if it was specified in the protocol
and uses an valid interaction test. Analysis of the lat-
ter, called improper subgroups, is, however, discour-
aged under any circumstance [43,51,54-56]. Analysis of
improper subgroups can mislead even when baseline
balance prevails. Subtle interactive effects can make
treatment arms within improper subgroups different in
terms of important prognostic features (baseline and
time based), no longer directly comparable, and make
this form of analysis prone to time-dependent bias
[57,58].
The bulk of the statistical analysis in Gomes et al.
divides the patients in terms of a post-randomization
event, namely, time to death. In Table 2 and later ana-
lyses, one of these subgroups is further decomposed in
terms of time to reach the clinic (0 to 6 hours or more
than 6 hours). Improper subgroups are formed within
improper subgroups and are again divided. The validity
of these analyses is methodologically suspect. The man-
ner in which the division is done also fosters conceptual
confusion. For example, cases who arrived at the clinic
within 6 hours but died within 6 hours, or those who
died within 6 hours but were on their way to the clinic
disappear from view. On top of that, all detailed analyses
of time to reach the clinic are, as noted earlier, not
based on a firm foundation in that this time is not well
defined and was routinely recorded at only two of the
four participating centers.
Table 4 Risk of death or PD by center and treatment
Center Artesunate (%) Placebo (%) RD (95% CI)
Africa-Handeni 54/726 (7.4%) 71/737 (9.6%) 2.2% (-0.8%, 5.2%)
Africa-Kilosa 27/1170 (2.3%) 31/1169 (2.7%) 0.3% (-1.0%, 1.7%)
Africa-Navrong 30/1145 (2.6%) 43/1093 (3.9%) 1.3% (-0.3%, 2.9%)
Bangladesh 45/3031 (1.5%) 45/2997 (1.5%) 0.1% (-0.6%, 0.7%)
Overall 156/6072 (2.6%) 190/5996 (3.2%) 0.6% (-0.3%, 1.4%) *
Note: Due to lack of relevant data, these analyses are not ITT analysis. Instead,
they use the subjects analyzed by Gomes et al. with death assessed by the
day of the 7-30 day follow up; *Random effects model estimates.
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If such practical problems are not present, is there a
better method to analyze the data? Using the data from
Figure one and Table two of Gomes et al., we show in
Table 5 how time to death can be incorporated into the
analysis in an unbiased manner that also reduces the
chance of false positive findings. Here, the final status of
each patient is classified into one of four categories
(dead within 6 hours, died after 6 hours; alive but with
PD; alive without PD). We compare the treatments for
this four category outcome variable by an overall chi-
square test. We also perform individual category com-
parisons, adjusting the p-values for multiple
comparisons.
We do this for two datasets. The top part of Table 5
shows the results for subgroup (iii), in line with the
inappropriate ITT analyses of the authors. This shows a
significant overall difference. Adjustment for multiplicity
shows that this effect is driven by a difference in PD
rates. The full ITT analysis is at the bottom of Table 5.
In this, we assumed, as in Figure one of Gomes at al.,
that the eight lost to follow-up placebo-group cases
were alive and without PD. This analysis points to a
level of variation consistent with chance. Observe that
when all the randomized subjects are considered, the
PD rates for the two groups are nearly the same.
Lack of data prevented us from doing a complete ITT
analysis of this form. Further, these analyses are tainted
by the design and implementation problems noted
above. These times to reach a referral clinic data are of
too poor a quality to yield useful conclusions. Bearing
these limitations in mind, we infer that a more compre-
hensive, unbiased, type I error protective analysis fails to
back up the main conclusion on the utility of pre-refer-
ral artesunate suppository for presumed severe malaria
drawn by Gomes at al.
Deciding upon ways of analyzing data after examining
the data is a common but serious flaw in the analysis of
clinical trial data [39]. Such data dredging increases the
chance of generating spurious findings. Gomes et al. is
replete with such practice. The p-values generated from
such analyses lack rigorous probabilistic interpretation.
Yet, they underlie the main conclusions reached by
them. A better course of action is to fit a multi-variate
regression model with pre-specified covariates and
appropriate interaction terms.
Analysis and Reporting Metric
Gomes et al. use the risk ratio as the main comparative
metric. When event rates are small (say, less than 5%),
as is the case here, it may convey an exaggerated picture
of the benefit of treatment. While there is debate among
statisticians about the relative utility of the two metrics,
we find arguments that the risk difference is preferred
in such circumstances more persuasive [59,60]. The
relative risk reduction for the main finding in the Sum-
mary of Gomes et al. is almost 50%, but the decrease in
absolute risk is 1.9 percentage points. The former looks
more impressive but is less useful in practical terms.
This point has been made specifically for malaria inter-
ventions as well [61,62].
The number needed to treat (NNT) - the inverse of
the risk difference - is a related metric. It is a suggested
helpful metric for binary outcomes in the official expla-
natory document accompanying the CONSORT state-
ment [14]. Gomes et al. do not report the NNT for the
main outcomes but raise the issue in the discussion sec-
tion. They state that they did not compute the NNT
because baseline risks vary. As we noted earlier, the
main data analyses of Gomes et al. were not stratified
by center. Varied baseline risks were thereby not taken
into account, and instead of weighted risk ratios, simple
overall risk ratios were given. Their rationale for not
computing the NNT is thus not consistent with doing
the main analyses in an unstratified manner. If baseline
risks are too variable to justify computing the NNT, that
also calls for stratified analysis. Such analysis, further, is
often warranted by design and effect measure heteroge-
neity considerations even when baseline risks do not
vary.
Using the valid ITT numbers from the bottom half of
Table 5, we find that the difference of risk for D or PD
between rectal artesunate and placebo is 0.004 (p =
0.095) with 95% CI being (-0.001,0.010). This translates
into an NNT of 250 with 95% CI equal to (NNTH 1000
to NNTB 10). For these ITT appropriate data, a risk
ratio based analysis does not as well give a significant
finding for this outcome. Of course, a better estimate of
the NNT would come from a stratified ITT analysis for
approximately fixed time window data. But the relevant
data are not found from the paper.
Table 5 Early death, late death or PD by treatment
Non-ITT Analysis
Status Artesunate Placebo RD p-value*
Death ≤ 6 hours 56 51 -0.001 1.00
Death > 6 hours 98 126 0.005 0.14
Alive with PD 2 13 0.002 0.01
Alive and No PD 5916 5806 -0.006 -
Total 6072 5996 0.01†
ITT Analysis
Status Artesunate Placebo RD p-value*
Death ≤ 6 hours 86 85 0.000 1.00
Death > 6 hours 172 203 0.004 0.26
Alive with PD 15 22 0.001 0.70
Alive and No PD 8681 8562 -0.004 -
Total 8954 8872 0.23†
Note: Late death (after 6 hours) assessed by day of the 7-30 day of follow up;
*Multiple-comparison adjusted; †Overall chi-square p-value.
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Reporting Style
The vague or inconsistent manner of reporting the
design and conduct of this trial were noted above. We
also saw how non-primary endpoints became primary
endpoints. Data analyses in the paper also shows exam-
ples of conceptual anomalies and reporting inconsisten-
cies. For example, while the main analyses excluded
those subjects with negative blood smears, for comput-
ing a risk difference, this subgroup is brought into the
picture to argue that the risk difference is larger than
what emerges from the computations. While stratifica-
tion was not done in the main analysis, it was done in a
subsidiary case; interaction testing for subgroup effects
was not performed in general but was done for one par-
ticular analysis; survival analyses were not done but a
curve appearing to depict it was presented; risk differ-
ence was not the main reporting metric but was
employed as such in a subsidiary analysis; etc.
Figure one of Gomes et al., the patient flow chart,
shows another instance of inappropriate reporting. Let
us explain. Any clinical trial screens people deemed
eligible but are, for some reasons, not enrolled. They
may not have the disease in question, may refuse to
participate, and so on. Such initial screening occurs in
hospital-based and community-based trials. Often
more people are excluded from a trial than included.
The rural trial of Yeboah-Antwi et al. [31] had a total
of 5108 children under five reporting to the recruiters.
But only 3125 were enrolled. The numbers of cases
excluded and the reasons for exclusions provide
important indicators of the external validity of the
trial. The patient flow chart is the main source for
such information.
The flow chart of Gomes et al., Figure one, lacks such
information, and gives the impression that everyone
who approached the recruiters was randomized. But
there are malaria cases with high fever who can take
oral medication, or cases with fever and diarrhea not
thought to be due to malaria. In such a large-sample
study, it is not likely that there were no cases who came
to the recruiters but were not randomized. It is more
likely that such cases were not recorded or were not
recorded consistently at all the centers. In the absence
this crucial information about exclusions, this flow chart
is a partially reported flow chart [13,14].
For clinical trials, the term pre-specified has a specific,
narrow meaning. It refers to entities specified at the
planning stage and noted in the protocol. This is how
Gomes et al. use it most of the time. But when they
refer to “pre-specified exclusions“ of cases from data ana-
lysis at the beginning of the Results section, it has a dif-
ferent meaning, referring to being specified after the
trial was over but before the results were unblinded for
the final analysis.
There is no mention of interim analysis in Gomes et
al. But from Kitua et al. [19] we learn that interim ana-
lyses were done but were not conclusive. We do not
know if the exclusions from data analysis and the use of
a composite outcome as a primary outcome in Gomes
et al. were determined prior to or after these interim
analyses. If it was the latter, an element of bias was
introduced.
The reporting style in Gomes et al. overall does not
facilitate illumination of the main results. Excessive
space is given to secondary issues. Key matters appear
in fine print. The reasoning is at times not clear. Infor-
mation is scattered across different papers and sources.
And what is said here is not always consistent with
what is said there.
Contextual Considerations
A clinical trial unfolds in a societal context. Apart from
the therapies under scrutiny, context-specific factors
usually affect the outcome of the disease at hand. For
example, the prognosis of severe malaria in children in
rural villages depends upon parental awareness; cost and
promptness of care; transport services; availability of
diagnostic tools, medication and hospital beds; quality of
case management; and competency and motivation of
health workers and hospital staff [19,63].
Protecting the welfare of people drawn into any phase
of a clinical trial is essential. The trial design and con-
duct may modify some contextual factors to serve this
end while the other factors are unchanged. Too many
changes render the trial findings not applicable to that
context. However, if even the gaping problems are left
to fester, the welfare of the participants is undermined.
Allowance for external validity has to balance concern
for patient welfare. Contextual changes in a multi-center
trial should reflect fairness across the centers and a
common standard for patient welfare.
In this section, we examine the contextual interven-
tions that Gomes et al. did or did not do. This allows us
to judge the trial’s external validity, and the degree of
protection of patient welfare. We also discuss a contex-
tual paradox that intruded into data analysis.
Contextual Interventions
The subjects in Gomes et al. encountered the trial-asso-
ciated contextual changes at four occasions: (a) prior to
enrollment; (b) at enrollment; (c) in transit to a referral
clinic; and (d) at the referral clinic.
Before the trial start, the investigators held community
meetings to educate and inform parents of potential
participants. Specifically, “the individual consent form,
use of placebo, and the importance of proceeding to the
referral clinic were discussed in detail and the trained
local village recruiters were introduced.” (See also Kitua
et al. [19]) This is as it should be. It is, however, not
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clear whether such a meeting was held at each of the
219 villages in the trial, and whether the meetings took
place in a similar fashion at all the four centers.
At enrollment, the cases encountered the local recrui-
ter. Using semi-trained workers in such a trial enhances
the applicability of its results. Diseases with grave mani-
festations and outcomes, though, require VHWs with
some prior training and sufficient experience to have
developed the skills and fortitude to handle seriously ill
children. VHWs need further training, as explained ear-
lier. If pre-referral artesunate for suspected severe
malaria is to be a real option, it will be implemented by
VHWs. Persons with no health-related background and
only a week of training are unlikely to be given such a
responsibility [6].
Above, we noted the deficiencies and vagueness of
Gomes et al. with regard to trainees and training, and
contrasted it with Yeboah-Antwi et al. [31] The WHO/
TDR website, however, declares that “the training,
supervision and monitoring of the resident village recrui-
ters for the purpose of the clinical trial was more rigor-
ous than that which would be the norm in many
community settings.” [3] This compares training in the
regular rural setting with that for an internationally
funded trial. Such a comparison is unwarranted because
not only does the latter have to abide by higher stan-
dards but it also has the resources to do so. We need to
know if the training, supervision and monitoring in
Gomes et al. trial was at par with or more rigorous than
the norm for malaria or severe malaria trials in rural
community settings. As noted earlier, such evidence has
not been given. The recruitment of clearly ineligible
cases, and the extent of missing data on key items we
have detected do not favor it.
For transport to clinic, the level of support at different
centers varied. In Tanzania, no support was given. In
Ghana, a “three-wheeled motorized transport was sta-
tioned at primary health centers to transfer patients to
the district hospital.” [19] It is unclear if any arrange-
ment for transport was made in Bangladesh.
Patients in Bangladesh, though, had stronger incen-
tives to proceed with haste to the health center. Supplies
of needed medications were stocked at the facilities in
the area. Treatment and hospitalization were well orga-
nized and free of charge. In Ghana, that was not so. In
Tanzania, where under the table payments for health
services at governmental facilities are common, an
unrealistic reliance was placed on the official policy that
care would be provided free. Also, specific measures to
ensure the supply of medicines were not taken. And,
everywhere, “[n]o change to the routine management of
patients at hospital was made.” [19]
Variable contextual interventions contributed to varied
levels of adherence to referral advice. Considering only
the young children with malaria, in Tanzania, 18% never
went to a clinic, while the same figures for Ghana and
Bangladesh were 5% and 2%, respectively. The varied
interventions lack a sound rationale. Severe malaria
requires prompt appropriate care. Increasing support
given to the parent raises the chance of the child’s being
taken to a clinic. The disparity among the centers
reflects, in our view, lack of required coordination by
the central organizing team. Or, it may be that these
were three separate trials with distinct designs that
which should have been published as three trials. Even
in that case, a well argued rationale is needed for each
trial.
The organizers knew of the possible dangers in
aspects of the routine management of severe malaria
[19]. In that respect, about 2000 of the 6000 patients
who reached a referral clinic in Africa, mainly in Tanza-
nia, and included in the analysis got intramuscular injec-
tions at an anatomically risky site. In eight cases, this
caused serious damage to the sciatic nerve. Considering
the cases excluded from the analysis, perhaps there were
more. Adequate guidelines and supervision at the health
clinics could have prevented this and other possible
harm that we do not know about.
Inappropriate contextual intervention, especially the
inadequate training of recruiters, perhaps had broader
consequences. The rate of D or PD among those slide
negative for malaria was 165/4648 (3.5%), among those
already immediately treated by injection for severe
malaria, it was 72/1110 (6.5%), and among (later) con-
firmed malaria cases, it was 346/12068 (2.9%) (chi-
square p < 0.0001) (Figure one, Gomes et al.). The D or
PD rate in cases with a prior injection was more than
twice the rate of the last subgroup (p < 0.001, adjusted
for multiple comparisons). The D or PD rate difference
between these subgroups is also larger than the differ-
ences between artesunate and placebo highlighted by
the authors. That is, the subgroups with either clearly
ineligible or potentially ineligible cases had significantly
higher D or PD rates. These higher rates may reflect the
underlying risk in these subgroups, or they may be due
to severely ill children being not handled appropriately,
treated needlessly, and sent off unassisted on a hazar-
dous trip when it was not called for. In any case, the
claim that benefits of trial participation outweighed
harm in these subgroups is subject to doubt. The varia-
tions in these subgroup level D or PD rates by center
are not reported.
We note that the BMJ editorial [6] describing this trial
as “remarkable“ also devoted most of its space to argue
that its findings may not be translatable into practice!
The case was made on three grounds: (i) the inadvisabil-
ity of setting up a parallel system (that is, outside of the
usual VHW framework) to deliver rectal artesunate; (ii)
Hirji and Premji Trials 2011, 12:188
http://www.trialsjournal.com/content/12/1/188
Page 13 of 19
the imperative, when a child is gravely ill, to ensure
rapid referral to a facility that can give required treat-
ment; and (iii) the question of how to deal with cases
who show signs of severe malaria but may not have it. It
thereby ends by praising Gomes et al. not for demon-
strating that pre-referral rectal artesunate is a sound
option in remote areas but for showing clearly that “sub-
stantial delays in treatment can have serious effects on
seriously ill children ...“ [6]. The latter, however, was
neither the main aim of this trial, nor something that
was backed with sound analysis by the authors.
The comment on Gomes et al. in The Lancet had
called for field studies to address essential practical
questions [2]. In the paper that addressed ethical issues,
Kitua et al. [19], even the authors of Gomes et al. argue
that the benefits of contextual interventions outweighed
the difference between artesunate and placebo. To quote
them: “Because of rapid hospital referral, malaria mor-
tality and morbidity decreased even without pre-referral
treatment.”
Drug resistance is relevant. The strong discourage-
ment of artemisinin monotherapy for uncomplicated
malaria instituted by the WHO is meant to counter the
emergence of resistant parasites. Gomes et al. also note
the issue. Yet they do not pay due attention to what
would happen if the rural areas are inundated with arte-
sunate only pills. The attendant risks are many. In lay
hands, they may be misused, overused and abused, and
so hasten the reduction of the efficacy of a currently
valuable remedy.
The WHO website, a response by the authors to a let-
ter, and the paper on trial ethics by Kitua et al. stress
that all the participants benefited from the conduct of
this trial. They had better care and lower risk of death
than would otherwise have been the case [3,19,64]. As
we showed above, grounds for doubting this claim exist.
Yet, even if it is valid, what does it say about the ratio-
nale for the trial?
A clinical trial is justified on the basis of an expecta-
tion of a meaningful difference in outcome, assurance of
the welfare and rights of participants, a realistic assess-
ment of eventual practical utility, good design and satis-
factory implementation. It cannot be justified simply on
the grounds of providing a benefit to the participants.
Say, a rural randomized trial of severe malaria to com-
pare a placebo suppository with a placebo skin ointment
is planned. After the initial therapy, the child is sent to
a health facility in an ambulance. Compared to a simi-
larly afflicted child left in the village, this child gets bet-
ter care and has improved chances of survival. That is
true. Yet why spend millions of dollars on it - and
multi-center international trials do cost millions of dol-
lars - when that money can pay for better transportation
for severely ill patients to health centers? If,
furthermore, the trial has major problems in design,
conduct, analysis and interpretation, the fact that all
who took part in it benefited in some way does not
serve to justify it.
Clinical trials must adhere to the basic ethical values
of society. We do not plan a trial to test whether
tobacco causes lung cancer. In the same fashion, we do
not need clinical trials to improve access to care for
severely ill children. An exclusive focus on clinical trials,
particularly drug trials, fosters a myopic vision towards
health care. Simpler and cheaper beneficial preventive
or facilitatory measures are set aside in favor of treat-
ments that have a marginal effect but which have been
evaluated by randomized trials. In Africa this tendency
has been carried to an extent that even the need for
rural children to wash their faces has to be tested in an
externally funded trial [65]. For internationally financed
trials whose resources easily exceed the annual budgets
of the health districts in which they take place, these are
daunting concerns.
The very conduct of trials within some contexts can
also generate a deleterious impact. Higher remuneration
draws scarce health personnel into the trials to a degree
that can compromise the care of regular patients. And
public health priorities are misdirected as well. With
more and more trials taking place in resource poor set-
tings, these are not minor issues [66].
Contextual factors matter, and need careful atten-
tion when planning a trial. Else, even when it has
been done according to high standards, its findings
may be turn out to be superfluous. The BMJ editorial
lauding this trial ends not with a call to promote rec-
tal artesunate but with a call to fix the “system failure“
that leads to delayed care [6]. The authors of Gomes
at al. make the same point in another paper when
they note that “[h]ealth system improvements lowered
the death rate.” [19] With its subtitle, “Delays to
treatment cost lives and quick fixes are not the
answer,” the BMJ editorial [6] effectively poses the
same question.
We have not come across a single paper that ques-
tions the major benefits of contextual interventions
designed to enhance rapid referral. The shortfalls in
such interventions and related matters we have noted
therefore cast a negative shadow on the practical utility
of Gomes et al.
A Contextual Paradox
The decision to include only confirmed cases of malaria
in data analysis in Gomes et al. derived from a filing
done with the US Food and Drug Administration (Sta-
tistical methods). It was, however, taken prior to
unblinding the results. The FDA filing concerned cases
with “acute malaria.” But all the centers enrolled cases
with “suspected acute malaria ...,” or “suspected severe
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malaria,” or a variation thereof (Methods part of the
Summary). The party that did this filing is not named.
Rectal artesunate as a pre-referral remedy for severe
malaria does not apply to the US context. There, if
malaria or severe malaria is suspected, a blood slide will
be read, and if positive, appropriate treatment adminis-
tered promptly. The pre-referral option is called for in
remote rural areas where severe malaria is suspected but
not confirmed, and where, moreover, parenteral treat-
ment is unavailable. By nature, it is a risk-reducing
intermediate therapy based on presumptive diagnosis.
Restricting data analysis only to confirmed malaria
cases then made the results appear less applicable to the
rural areas of poor nations. This paradoxical deletion of
about a quarter of subjects from analysis not only vio-
lated the ITT principle but compromised its external
validity as well. That could have been avoided if all ran-
domized subjects were included in the analysis. For the
erroneously enrolled cases (with an immediate prior
injection for malaria), the results of both including and
excluding them in the analysis should have been pre-
sented. Also, note that we are unsure what proportion
of the confirmed malaria cases fulfilled the WHO cri-
teria for severe malaria.
It is unclear why this external factor - the filing to the
FDA - was the main factor in deciding whom to exclude
from data analysis. Gomes et al. is a scientific report,
not an FDA application.
We end this section by clarifying that the term exclu-
sion as used above does not imply practical neglect.
Under a patient welfare protective design, cases present-
ing with severe symptoms and deemed eligible should
be offered assistance to secure prompt treatment. But
such help should also be given to the severe cases pre-
senting to the recruiter but who are not deemed eligible
for the trial. The latter, however, would not be enrolled
in the trial or randomized. But their numbers and rea-
sons for exclusion should be noted in the flow chart.
Conclusions
This paper has shown that many facets of the study of
Gomes et al. - design, conduct, analysis, interpretation
and practical utility - had major flaws. The design flaws
were manifested in the absence of well specified inclu-
sion and exclusion criteria, outcome variables that were
pre-specified, sample size computation, concrete time
window for follow-up, and clear information on recrui-
ters and training. Between center variability in number
of blood slides, age of subjects enrolled, provision of
transport and good care lacked a clear rationale. Short-
falls in implementation were evident through enrollment
of clearly ineligible subjects and high missing levels for
key data. The time window in the analysis mixed up
short term and medium term mortality, and the survival
analysis was not done. Excluding a third of the rando-
mized cases from analysis not only violated the ITT
principle but also compromised external validity, parti-
cularly since the exclusions stemmed from a contex-
tually inappropriate factor. While the needed overall
stratified analysis was not done, an excessive number of
post-hoc subgroup analyses, many based on a post-ran-
domization event, were done. An unbiased reanalysis of
available trial data did not support the conclusions of
the paper. The manner of reporting also left a lot to be
desired. Essential information is publicly unavailable.
Some information is internally contradictory. The con-
textual interventions, or lack thereof, did not protect
patient welfare as it ought to have been protected, and
because there was no clear rationale for their variability,
compromised the applicability of the findings of the
study.
Some of the problems we identified had a greater
impact on the trial’s scientific validity than others. Some
introduced bias, some compromised external validity,
some did both, and some were in the realm of reporting
problems. It is generally agreed that a few trial features
like adequacy of concealment of randomization, and the
extent and pattern of missing data can have a major
impact on scientific validity [67]. There is also agree-
ment that poor statistical analysis can affect the validity
and importance of the findings of a trial [68]. But a
broader consensus about which problems have a major
or greater impact on validity does not exist. For exam-
ple, researchers differ in their judgment of the value of
relative risk and risk difference as reporting metrics.
For Gomes at al., we do not list the problems in order
of importance. Many of them are interrelated. Further,
we focus on the assessment that emerges from viewing
them in their totality. We hold that taken as whole, the
problems we uncovered severely compromise the scien-
tific validity of the trial, and the applicability of its
findings.
The comment in the Lancet on this trial declared: “If
there are a handful of important papers every decade
that will influence the way malaria is treated, this is one
of them.” [2] Based on what we have shown, we firmly
disagree with this characterization. On the contrary, we
deem Gomes et al. as an extensively flawed trial whose
conclusions and practical applicability remain subject to
appreciable doubt.
It is sobering to note that problems of this scope and
magnitude occurred even though the trial had a two-
year preparatory and planning phase, noted authorities
in the field were involved, it was coordinated by a glob-
ally esteemed institution in tropical diseases research,
and was overseen by a reputable clinical trial center
with leading experts and long experience in trial design,
analysis and reporting. One of their key tasks was to
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harmonize the design features between the trial centers.
That could have been done better.
Historically, an excess of poor quality trials was asso-
ciated with an excessive number of small size trials. In
some fields, large size trials have generally been better
quality trials though this relationship between trial qual-
ity and size does not always hold [69,70]. Yet, a large
multi-center trial with adequate resources and expertise
is an opportunity to produce reliable findings, set a high
methodological standard, and even introduce methodo-
logical innovation [54].
Gomes at al. represents the culmination of a ten year
effort by dedicated researchers with thousands of parti-
cipants on the ground. The quality of the final product
is then all the more distressing to contemplate. A stu-
pendous opportunity to gather reliable information to
enhance public health that does not arise often was
regrettably missed.
Our verdict on this trial has some general implica-
tions. First, poor quality trials continue to appear even
in reputable medical journals [71,72]. This trial appeared
in a premier journal which subscribes to the current
standards for quality and requires trial authors to adhere
to the CONSORT statement. Yet, a paper about a major
health issue but with grave flaws not only got into print,
but also went on to secure high praise and win a major
award. Some flaws could have been easily detected if the
CONSORT checklist was applied. Our paper adds to the
series of cases of recent papers the scientific community
failed to review adequately prior to publication. It thus
underscores the need to continually scrutinize and
improve the peer review process [73]. The journals in
question may also need to examine the process by
which this paper was reviewed.
Second, we stress that in this era of electronic publish-
ing - when journals and organizations put supplemen-
tary material on web pages - and of greater awareness
about the need for transparency, lack of space is not a
valid reason for the absence of critical information. Note
also that the information about sample size calculation
and eligibility criteria for this trial would have taken
much less space as compared to the extensive space the
authors gave to subsidiary secondary analyses.
Third, our paper underscores the proposition that
assessing trial quality from a checklist is not sufficient
to obtain a valid judgment of its quality [74]. A trial can
fulfill all or most of the checklist criteria for a good
quality trial. Yet, it can be deeply flawed. And, in some
cases, the situation may perhaps be the other way
around. Well designed and validated checklists are
needed, but they should be supplemented with an in-
depth evaluation.
Fourth, ITT analysis is a valuable tool to protect the
control of bias achieved through randomization, avoid
attrition and other biases, and enhance external validity.
Yet, it continues to be misinterpreted and misutilized
[75-77]. An analysis based on removal of a third of ran-
domized subjects from a large trial that is still labeled
an ITT based analysis represents an extreme case of
this. Also, despite the numerous cautions given about
subgroup analysis, it continues to prevail. Health and
medical journals need to do more to bring practice in
line with principles.
Fifth, the results of Gomes et al., the various commen-
taries on it, and associated papers as well as our paper
point to the importance of considering contextual fac-
tors when planning a trial. There is, in particular, a criti-
cal need in most poor nations for regular general health
education via the mass media, public meetings and adult
education campaigns. Yet, this matter has had a low
priority in the recent years. When external funds permit,
messages on HIV/AIDS or malaria are heard on the
radio. While enticing promotions of soft drinks and
chewing gum permeate the air in the most far away
areas, comprehensive education on health, hygiene and
nutrition is all but absent. Health literacy is generally at
a low level and people harbor all manner of beliefs relat-
ing to health [78]. A systematic review of qualitative
malaria studies identified several barriers to effective
prevention and treatment, one being the belief that a
child who is having convulsions may “die if given an
injection or taken to a hospital.” [79] For introduction of
rectal artesunate therapy, Kaona and Tuba [80] suggest
effective prior sensitization among mothers and health
workers.
Promoting prompt treatment for seriously ill children
should not await the conduct of a clinical trial. Rather,
it should be an ongoing educational activity done effec-
tively with local funds. Correspondingly, the educational
effort of the type done by Gomes et al. to improve
adherence to referral must be a part of a wider process
of system change noted by the BMJ editorial [6]. Educa-
tion done specifically for a clinical trial may have a
selective focus, and thus be of questionable long term
utility.
Lack of access to the original data is a major limita-
tion of our paper. An independent evaluation of detailed
trial records is thereby in order. A reanalysis of the data
of Gomes et al. using appropriate methods should fol-
low. Only in that way can more well founded conclu-
sions be drawn. The contextual concerns we have raised
need attention as well.
We end by emphasizing that our paper does not take
a position on the use or otherwise of rectal artesunate
as a pre-referral treatment for suspected severe malaria.
Our stand is that this question is too important to be
decided from an inadequately designed, poorly con-
ducted, erroneously analyzed, and selectively interpreted
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study. The welfare of the children and adults with or at
risk for severe malaria can only be served by trials that
are meticulously planned, performed according to sound
scientific principles, and analyzed appropriately, and
whose contextual ramifications are unimpeachable. The
recommendation on rectal artesunate as a pre-referral
treatment for suspected severe malaria needs to await
the results of such a trial.
At the same time, we must ponder: Should such a trial
be carried out or should the focus be on contextual
changes to promote health education and speedier
access to treatment? The latter benefits not just the
cases with severe malaria but many more who require
urgent attention. The question is: Should the future
research and policy agenda derive from the endorsement
of rectal artesunate as a pre-referral in the Summary of
Gomes et al? Or should it derive from the last sentence
of the same paper, which declares that “accessible clinics
and good organization within villages and within hospi-
tals can greatly reduce malaria mortality and morbidity
even without pre-referral treatment.” The emergent
agendas, one directed towards development of improved
pre-referral suppositories, [81] and the other towards
“addressing access barriers among the poor and the vul-
nerable,” [82] are quite divergent.
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